1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cystic fibrosis

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance [TA276] Published date: 27 March 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Related NICE guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Update information
Download guidance (PDF)

Guidance

  • Next

6 Related NICE guidance

6 Related NICE guidance

  • Mannitol dry powder for inhalation for treating cystic fibrosis (2012) NICE technology appraisal guidance 266.

  • National Institute for Health and Care Excellence (NICE)

  • Next